We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ISTA Pharmaceuticals Announces U.S. Patent Allowance for PROLENSA™ in the United States

News   Jan 06, 2012

 
ISTA Pharmaceuticals Announces U.S. Patent Allowance for PROLENSA™ in the United States
 
 
 

RELATED ARTICLES

Antidepressant Based on Ketamine Gets Backing from FDA Advisory Group

News

A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.

READ MORE

Imaging Agent Could Help Measure Effectiveness of Breast Cancer Therapy Earlier

News

Researchers report that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been found to successfully measure changes in progesterone receptor levels resulting from a short-course estrogen treatment, also known as an estradiol challenge.

READ MORE

> 500 000 US Breast Cancer Deaths Averted Over Three Decades

News

Latest U.S. estimates indicate that since 1989, hundreds of thousands of women's lives have been saved by mammography and improvements in breast cancer treatment.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE